Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency

BACKGROUND: Daclizumab is a humanized monoclonal antibody that blocks CD25, the high affinity alpha subunit of the interleukin-2 receptor. Daclizumab therapy targets T regulatory cell and activated effector T cell proliferation to suppress autoimmune disease activity, in inflammatory conditions like...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, Leisa Rebecca, Slade, Charlotte A., Ojaimi, Samar, Barnes, Sara, Fedele, Pasquale, Smith, Prudence, Marum, Justine, Lunke, Sebastian, Stark, Zornitza, Hunter, Matthew F., Bryant, Vanessa L., Low, Michael Sze Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196561/
https://www.ncbi.nlm.nih.gov/pubmed/30377434
http://dx.doi.org/10.1186/s13223-018-0272-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196561/
https://www.ncbi.nlm.nih.gov/pubmed/30377434
http://dx.doi.org/10.1186/s13223-018-0272-7

Ejemplares similares